I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $476.3M
Chilly Mazarin, France
The Series B financing was led by Innoven Partners, and included Societe Generale Asset Management
The financing was provided by Hercules Technology Growth Capital Inc.
The financing was provided by WRF Capital
Investors in the Series A financing included Canaan Partners and Burrill Associates
Research Triangle Park, N.C.
Finistere Partners led the Series C round, which included Intersouth Partners, Polaris Venture Partners, Boston Millennia Partners, Hunt Ventures and Eastman Ventures
Syngenta AG acquired a minority equity stake in Avidex with the £5M investment
The Series A financing was led by Pfizer's Strategic Investments Group and included Lilly Ventures, RK Ventures LLC and BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania
Biofusion purchased 5% of Axordia in the deal, increasing its stake to 36%
This Series D financing was co-led by NIF SMBC Ventures and Mitsui Ventures and included Nikko antfactory KK, MBL Venture Capital, Mizuho Capital, Nomura Securities and Marubeni
Investing in the Series D financing were Argonaut Private Equity, Ventry Industries LLC, Gainesbourgh Investments, James L. Waters and Stata Ventures, all existing investors
The Series B financing included new investor Finistere Partners along with existing investors Burrill & Co., Prolog Ventures, Redmont Venture Partners and Harris & Harris Group
The Series A financing was co-led by Domain Associates and Pappas Ventures and included Triathlon Medical Ventures and Pearl Street Venture Funds
New investors DH Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG participated in the Series B financing, which will total up to €22M
The Series A financing was led by First Analysis Corp. and Prolog Ventures and included new investor Stonehenge Capital and existing investor Novartis Venture Fund
GlobeImmune added $4.1M to the $34.3M raised in November in a Series B financing; investors included PAC-LINK Bio Venture Capital, China Investment and Development and Yasuda Enterprise Development
Guava obtained the secured debt financing from Hercules Technology Growth Capital Inc.; it also obtained a one-year credit line of $4.5M from Hercules
The Series C financing round was led by company Chairman Nick Mitsakos and included private investors
The Series C financing was led by Inventages Venture Capital Investments Inc. and included Biosciences VTC and existing investors Avlar BioVentures, Oxford Technology VCT, Generics Asset Management and Yorkshire Fund Managers
The funding was provided by InnovationsKapital
The Series C financing was led by Brookside Capital and included previous investors Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Bay City Capital and Skyline Ventures, as well as Alexandria Real Estate Equities
Research Triangle Park, N.C.
The Series B financing was led by Sevin Rosen Funds and included existing investors The Aurora Funds and The Trelys Funds and new investor Harris & Harris Group
Nabriva was spun off from Sandoz GmbH; Nomura Phase4 Ventures led the Series A round, which included HBM, the Wellcome Trust, Global Life Science Ventures and Novartis Venture Fund
South San Francisco
Investors in the $25M second tranche of the Series C financing included Apax Partners, Domain Associates, New Enterprise Associates, ProQuest Investments, Versant Ventures and Sofinnova Ventures; $35M was raised in the first Series C tranche in January 2004
The Series A financing was co-led by Domain Associates and Thomas, McNerney & Partners
The undisclosed investment was provided by the Carilion Biomedical Institute
WFD Ventures Ltd. provided the undisclosed funding
Investing in the Series A financing were GSB Ventures, Endeavour i-Cap, No8 Ventures, Alta Partners, Genentech Inc. and F. Hoffmann-La Roche Ltd.
Protein Sciences Corp.
Investing in the round were Diamyd Medical AB, Pacific Rim Ventures Co. Ltd. and a family fund
New Enterprise Associates and OrbiMed Advisors provided funding for the new company, which acquired the product formulation and development business of Shire Laboratories Inc.
Company said it completed the initial closing of a Series D financing; investors included LD Pensions, Essex Woodlands Health Ventures, Scandinavian Life Science Venture, Novo A/S, Vaekstfonden and Takeda Research Investment Inc.
Sanderling Ventures invested in the Series A financing and would add more if milestones are reached
The Series B financing round was led by ING Corporate Finance, and included HSS Ventures, ITX Corp., Banque Generale de Luxembourg, Baekelands Fonds 2, SRIW and Partners@Venture, as well as all existing investors
Founding investor Forward Ventures led the Series A financing, which also included New Leaf Venture Partners and BB Biotech Ventures II
The Series B financing was led by EMBL Ventures and included other new investors Bayern Kapital and KfW and existing investors Future Capital AG, Entrepreneurs Fund, 3i Group Investments LP and private investors
South San Francisco
Duff, Ackerman & Goodrich led the Series E round, which included Intel Capital and existing inves- tors Kleiner Perkins Caufield & Byers, Texas Pacific Group Ventures, the Sprout Group, Burrill & Co., Integral Capital Partners and Bay Area Equity Fund
The Series B round was led by Sanderling Ventures and included Atlas Venture, Ventech and CDC Entreprises Innovation; the company resulted from the merger of Xytis Pharmaceuticals Ltd. and Remergent Inc.
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.